<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00373373</url>
  </required_header>
  <id_info>
    <org_study_id>KKS/INNERE_A/AML2006</org_study_id>
    <secondary_id>EudraCT Number: 2005-005966-35</secondary_id>
    <secondary_id>Sorafenib in AML</secondary_id>
    <nct_id>NCT00373373</nct_id>
  </id_info>
  <brief_title>Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized, Multi-center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine, whether the addition of Sorafenib to
      standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results
      (event free survival).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Event Free Survival of all AML patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Event Free Survival of AML patients with Flt3-ITD mutations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Event Free Survival of the patients in each of the four strata (Flt3 Non-ITD/NPM1 WT, Flt3 Non-ITD/NPM1 mut, Flt3 ITD/NPM1 WT, Flt3 ITD/NPM1 mut)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival of AML patients with Flt3-ITD mutations</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival of all AML patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Remission in all AML patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Molecular Remission in all AML patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Minimal Residual Disease in all AML patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Biomarkers indicating the course of disease</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chemotherapy + Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chemotherapy + Sorafenib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>2 x 400 mg/d</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Chemotherapy + Placebo</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed AML (except APL) according to the FAB and WHO
             classification, including AML evolving from MDS or other hematologic diseases and AML
             after previous cytotoxic therapy or radiation (secondary AML)

          -  Bone marrow aspirate or biopsy must contain &gt;= 20% blasts of all nucleated cells, with
             the exception of AML FAB M6, where &gt;= 30% of non-erythroid cells must be leukemic
             blasts

          -  Age &gt;= 61 years

          -  Informed consent, personally signed and dated to participate in the study

          -  Male patients enrolled in this trial must use adequate barrier birth control measures
             during the course of the Sorafenib treatment and for at least 3 months after the last
             administration of Sorafenib

        Exclusion Criteria:

          -  Central nervous system manifestation of AML

          -  Cardiac Disease: Heart failure NYHA III° or IV°; active coronary artery disease (MI
             more than 6 months prior to study entry is permitted); serious cardiac ventricular
             arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          -  Chronically impaired renal function (creatinin clearance &lt; 30 ml/min)

          -  Chronic pulmonary disease with relevant hypoxia

          -  Inadequate liver function (ALT and AST &gt;= 2.5 x ULN)

          -  Total bilirubin &gt;= 1.5 x ULN

          -  Resting blood pressure (BP) consistently higher than systolic 160 mmHg and/or
             diastolic 95 mmHg

          -  Any severe concomitant condition which makes it undesirable for the patient to
             participate in the study or which could jeopardise compliance with the protocol

          -  Uncontrolled active infection

          -  Concurrent malignancies other than AML

          -  Previous treatment of AML except hydroxyurea and up to 2 days &lt;= 100 mg/m²/d
             cytarabine

          -  Known HIV and/or hepatitis C infection

          -  Evidence or history of CNS disease, including primary or metastatic brain tumors,
             seizure disorders

          -  Thrombotic or embolic events such as cerebrovascular accident or pulmonary embolism
             within 1 year of study entry

          -  Evidence or history of severe non-leukemia associated bleeding diathesis or
             coagulopathy

          -  History of organ allograft

          -  Concomitant treatment with kinase inhibitors, angiogenesis inhibitors and Myelotarg

          -  Patients with major surgery, open biopsy or significant traumatic injury within 4
             weeks of start or first dose

          -  Serious, non-healing wound, ulcer or bone fracture

          -  Allergy to study medication or excipients in study medication

          -  Investigational drug therapy outside of this trial during or within 4 weeks of study
             entry

          -  Patients who are not eligible for standard chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert Serve, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der J.W. Goethe Universität Frankfurt, Med. Klinik II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin, Med. Klinik III</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH, Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus der TU Dresden, Medizinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital, Medizinische Klinik II</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Zentrum für Innere Medizin, Medizinische Klinik und Poliklinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität Frankfurt am Main, Medizinische Klinik II</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus St. Georg, Hämatologische Abteilung</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Med. Klinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität, 3. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps Universität, Abteilung für Hämatologie, Onkologie und Immunologie</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Hämatologie und Onkologie Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München, Medizinische Klinik III</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Medizinische Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg, 5. Medizinische Klinik Einheit für Knochenmarktransplantation</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Regensburg, Abteilung für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch Krankenhaus Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julius-Maximilians-Universität Würzburg, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Würzburg</city>
        <zip>97979</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2006</study_first_submitted>
  <study_first_submitted_qc>September 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2006</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hubert Serve (Principal Investigator)</name_title>
    <organization>Klinikum der J.W. Goethe Universität Frankfurt, Med. Klinik II</organization>
  </responsible_party>
  <keyword>Sorafenib</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Flt3</keyword>
  <keyword>AML</keyword>
  <keyword>Kinase Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

